000 | 01406na a2200241 4500 | ||
---|---|---|---|
003 | H12O | ||
005 | 20180417112304.0 | ||
008 | 130622s2012 xxx||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_aGómez Martín, Carlos _91064 _eOncología Médica |
||
245 | 0 | 0 |
_aIncidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. _h[artículo] |
260 |
_bClinical & translational oncology, _c2012 |
||
300 | _a14(9):689-97. | ||
500 | _aFormato Vancouver: Gómez-Martin C, Sánchez A, Irigoyen A, Llorente B, Pérez B, Serrano R, et al. Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clin Transl Oncol. 2012 Sep;14(9):689-97. | ||
501 | _aPMID: 22855151 | ||
504 | _aContiene 27 referencias | ||
520 | _aHand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy. | ||
710 |
_9303 _aServicio de Oncología Médica |
||
773 | 0 | _g | |
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/4/pc4436.pdf _ySolicitar documento |
||
942 |
_n0 _2ddc _cART |
||
999 |
_c4436 _d4436 |